NCT01133704View on ClinicalTrials.gov

Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

March 31, 2003

Study Completion Date

May 31, 2005

Conditions
Hormone-Refractory Prostate Cancer
Interventions
BIOLOGICAL

sipuleucel-T

BIOLOGICAL

APC-Placebo

Sponsors

Lead Sponsor

Dendreon
All Listed Sponsors
lead

Dendreon

INDUSTRY

NCT01133704 - Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter